AdultPediatricGeriatricDosage Forms & Strengths tablet: Schedule IV 3.75mg 7.5mg 15mg Anxiety 30 mg/day PO in divided doses; adjust dose gradually within range of 15-60 mg/day When administered as single daily HS dose, initial dosage is 15 mg; after initial dose, response of patient may require subsequent dosage adjustment Seizure 7.5 mg PO q8hr; increase by < 7.5 mg/week; 90 mg/day maximum Acute Alcohol Withdrawal Day 1: Initial 30 mg PO once, THEN 30-60 mg in divided doses, no more than 90 mg Day 2: 45-90 mg PO in divided doses Day 3: 22.5-45 mg PO in divided doses Day 4: 15-30 mg PO in divided doses Day 5 onwards: 7.5-15 mg PO in divided doses Discontinue when stableDosage Forms & Strengths tablet: Schedule IV 3.75mg 7.5mg 15mg Partial Seizures <9 years: Not recommended 9-12 years: 7.5 mg PO BID initially; increase by <7.5 mg qWeek to 60 mg/day maximum >12 years: As in adultsNot drug of choice in elderly because of long-acting metabolite; long-acting benzodiazepines associated with falls in elderly Anxiety 7.5 mg PO qDay or q12hrInteraction CheckerEnter a drug name and clorazepateNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (23)abametapirabametapir will increase the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.apalutamideapalutamide will decrease the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, clorazepate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.benzhydrocodone/acetaminophen and clorazepate both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine subdermal implantbuprenorphine subdermal implant and clorazepate both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine transdermalbuprenorphine transdermal and clorazepate both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine, long-acting injectionbuprenorphine, long-acting injection and clorazepate both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatecalcium/magnesium/potassium/sodium oxybatesclorazepate, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.conivaptanconivaptan will increase the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.enzalutamideenzalutamide will decrease the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.fexinidazolefexinidazole will increase the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.hydrocodonehydrocodone, clorazepate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.idelalisibidelalisib will increase the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substratesivosidenibivosidenib will decrease the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.lonafarniblonafarnib will increase the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with sensitive CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling.lopinavirlopinavir will increase the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.metoclopramide intranasalclorazepate, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.olopatadine intranasalclorazepate and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. selinexorselinexor, clorazepate. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sodium oxybateclorazepate, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.sufentanil SLsufentanil SL, clorazepate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.tucatinibtucatinib will increase the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.valerianvalerian and clorazepate both increase sedation. Avoid or Use Alternate Drug.voxelotorvoxelotor will increase the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.Monitor Closely (246)acrivastineacrivastine and clorazepate both increase sedation. Use Caution/Monitor.albuterolclorazepate increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.alfentanilclorazepate and alfentanil both increase sedation. Use Caution/Monitor.alprazolamalprazolam and clorazepate both increase sedation. Use Caution/Monitor.amisulprideamisulpride and clorazepate both increase sedation. Use Caution/Monitor.amitriptylineclorazepate and amitriptyline both increase sedation. Use Caution/Monitor.amobarbitalamobarbital and clorazepate both increase sedation. Use Caution/Monitor.amobarbital will decrease the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.amoxapineclorazepate and amoxapine both increase sedation. Use Caution/Monitor.apomorphineclorazepate and apomorphine both increase sedation. Use Caution/Monitor.arformoterolclorazepate increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.aripiprazoleclorazepate and aripiprazole both increase sedation. Use Caution/Monitor.armodafinilclorazepate increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.asenapineasenapine and clorazepate both increase sedation. Use Caution/Monitor.asenapine transdermalasenapine transdermal and clorazepate both increase sedation. Use Caution/Monitor.atazanaviratazanavir increases levels of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Potential for increased toxicity. Use alternatives if available. Consider lowering benzodiazepine dose.avapritinibavapritinib and clorazepate both increase sedation. Use Caution/Monitor.azelastineazelastine and clorazepate both increase sedation. Use Caution/Monitor.baclofenclorazepate and baclofen both increase sedation. Use Caution/Monitor.belladonna and opiumclorazepate and belladonna and opium both increase sedation. Use Caution/Monitor.belzutifanbelzutifan will decrease the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. benperidolclorazepate and benperidol both increase sedation. Use Caution/Monitor.benzphetamineclorazepate increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.bosentanbosentan will decrease the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.brexanolonebrexanolone, clorazepate. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexpiprazole and clorazepate both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and clorazepate both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and clorazepate both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and clorazepate both increase sedation. Use Caution/Monitor.buprenorphineclorazepate and buprenorphine both increase sedation. Use Caution/Monitor.buprenorphine buccalclorazepate and buprenorphine buccal both increase sedation. Use Caution/Monitor.buprenorphine subdermal implantclorazepate increases toxicity of buprenorphine subdermal implant by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Studies have shown that the combination of benzodiazepines and buprenorphine altered the usual ceiling effect on buprenorphine-induced respiratory depression, making the respiratory effects of buprenorphine appear similar to those of full opioid agonists. There have been postmarketing reports of coma and death with coadministration of buprenorphine and benzodiazepines. In many, but not all of these cases, buprenorphine was misused by self-injection. If a benzodiazepine must be used for an indication other than seizures, lower the benzodiazepine initial dose and cautiously titrate to clinical response.buprenorphine, long-acting injectionclorazepate increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.butabarbitalbutabarbital and clorazepate both increase sedation. Use Caution/Monitor.butalbitalbutalbital and clorazepate both increase sedation. Use Caution/Monitor.butorphanolclorazepate and butorphanol both increase sedation. Use Caution/Monitor.caffeineclorazepate increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbamazepinecarbamazepine will decrease the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.carbinoxaminecarbinoxamine and clorazepate both increase sedation. Use Caution/Monitor.carisoprodolclorazepate and carisoprodol both increase sedation. Use Caution/Monitor.cenobamatecenobamate will decrease the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.cenobamate, clorazepate. Either increases effects of the other by sedation. Use Caution/Monitor.ceritinibceritinib will increase the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.chloral hydrateclorazepate and chloral hydrate both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and clorazepate both increase sedation. Use Caution/Monitor.chlorpheniraminechlorpheniramine and clorazepate both increase sedation. Use Caution/Monitor.chlorpromazineclorazepate and chlorpromazine both increase sedation. Use Caution/Monitor.chlorzoxazoneclorazepate and chlorzoxazone both increase sedation. Use Caution/Monitor.cimetidinecimetidine increases levels of clorazepate by decreasing metabolism. Use Caution/Monitor.cinnarizinecinnarizine and clorazepate both increase sedation. Use Caution/Monitor.clarithromycinclarithromycin will increase the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.clemastineclemastine and clorazepate both increase sedation. Use Caution/Monitor.clobazamclorazepate, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipramineclorazepate and clomipramine both increase sedation. Use Caution/Monitor.clonazepamclonazepam and clorazepate both increase sedation. Use Caution/Monitor.clonidineclonidine, clorazepate. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects.clozapineclorazepate and clozapine both increase sedation. Use Caution/Monitor.cobicistatcobicistat will increase the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dose of clorazepate if necessarycodeineclorazepate and codeine both increase sedation. Use Caution/Monitor.crofelemercrofelemer increases levels of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.cyclizinecyclizine and clorazepate both increase sedation. Use Caution/Monitor.cyclobenzaprineclorazepate and cyclobenzaprine both increase sedation. Use Caution/Monitor.cyproheptadinecyproheptadine and clorazepate both increase sedation. Use Caution/Monitor.dabrafenibdabrafenib will decrease the level or effect of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.dantroleneclorazepate and dantrolene both increase sedation. Use Caution/Monitor.daridorexantclorazepate and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darunavirdarunavir increases levels of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Use alternatives if available. Consider lowering benzodiazepine dose.desfluranedesflurane